Strategy That Drives Execution

Drug Development Strategy

Strategy is an interrelated set of choices required for achieving a goal. We apply proven strategy frameworks from Peter Drucker, Michael Porter, Roger Martin, A.G. Lafley, Renée Mauborgne, and W. Chan Kim into actionable tools for early-stage drug and platform developers. This empowers researchers to build Target Product Profiles and cost-conscious roadmaps for their developments.

Target Product Profiles (TPPs)

A TPP defines your product's characteristics and the patient populations it will serve. It guides development activities and explains the drug's features to key stakeholders.

Strategy Sprints

These short interactive sessions are designed around the principle that you learn best by doing. In less than six hours, participants build a version 1 development strategy and TPP. They leave with tangible outputs that move progress forward.

• EPD-01: Strategy. One framework and one iterative process to kick-start execution.
• EPD-02: TPP. Define your drug characteristics, pressure test your ideas and identify evidence gaps.

Pitch Scrubs

A comprehensive evaluation of your investor or grant deck. We pressure-test your deck, slide-by-slide, and score your pitch investment readiness across 8–12 stage-specific domains tailored to your development stage.

• 90-minute slide-by-slide pitch scrub
• Investment readiness score
• Top three strengths, weaknesses, & evidence gaps
• Various packages that match your stage, timeline, and depth of support needed

Project X

Coming soon! The fundamental problem in decision-making is that we feel like we never have enough data to make a decision. The volume of open-source scientific data is enormous, yet it is fragmented across numerous databases that were never designed to communicate with one another. Our solution is simple: provide researchers with an elegant solution to access structured data and insights from open-source databases.